Jeff Behrens, MS, MBA – President and CEO, Board of Directors

Jeff joined Sialix in May 2012.  From 2009 to 2012, he served as Senior Director of Business Development & Operations for Edimer Pharmaceuticals, a Third Rock-funded orphan drug company, where he oversaw manufacturing, finance, business development, and academic research collaborations. Prior to Edimer, Jeff worked at Alnylam as Director, Strategic Alliances and at Biogen Idec as co-founder and Head of Business Operations at the Biogen Idec Innovation Incubator. Jeff has an MBA from MIT Sloan and a MS from the joint Harvard/MIT Division of Health Sciences and Technology.  Jeff was previously the founder and CEO of The Telluride Group, a Newton, MA based managed services IT provider to the healthcare industry that was sold to mindSHIFT Technologies (funded by Fidelity) in 2003.

Julie Hermann, MS, MBA – Director, Business Development & Operations

Julie joined Sialix in September 2012.  Prior to Sialix, Julie held various positions in strategy and operations management at Frankel Group, McKinsey & Company, Amgen, and Cerner Corporation. Julie has an MBA from MIT Sloan and a MS from the joint Harvard/MIT Division of Health Sciences and Technology.

Ana Paula Galvao da Silva, PhD – Senior Research Scientist

Ana joined Sialix in June 2013. She completed her Bachelors at Federal University of Pernambuco, Brazil, and doctorate at University of São Paulo, Brazil. Prior to joining Sialix, Ana was a postdoc fellow in immunology at Stanford University, and a research scientist at Tocagen and AnaptysBio, where she led the discovery efforts of four monoclonal antibodies in preclinical development.

Darius Ghaderi, PhD – Senior Research Scientist

Darius joined Sialix in November 2009.  Darius completed his Diploma degree at Ruhr-Universität Bochum, Germany in the Hatt lab, and his PhD at the Freie Universität Berlin, Germany in the lab of Prof. Werner Reutter.  Prior to joining Sialix, Darius worked as a postdoctoral fellow in the Gagneux lab (UCSD) studying the impact of the loss of Neu5Gc on human fertility and evolution, and in the lab of Prof. Ajit Varki (UCSD) studying presence of Neu5Gc in FDA- approved biotherapeutics and its impact on immunogenicity and efficacy.

Mai Zhang, MD, PhD – Senior Research Scientist

Mai joined Sialix in August 2010 and is leading the scientific development of Sialix’s nutraceutical program.  She received her medical degree in China, and then pursued her PhD degree at the University of California, San Diego in Biomedical Sciences. At UCSD, Mai studied the effects of Sialic acid and the receptors in the immune system in Dr. Ajit Varki’s lab. Prior to joining Sialix, Mai also was a post-doc fellow at Johnson & Johnson, where she worked on histamine H4 receptor and its function on immune diseases, and a research scientist at Nexbio, where she worked on drug discovery projects including a flu therapeutic targeting sialic acid.

Ajit Varki, MD - Co-Founder, Board of Directors

Dr. Varki is currently the Distinguished Professor of Medicine and Cellular and Molecular Medicine, and Co-Director of the Glycobiology Research and Training Center at UCSD.  Dr. Varki received basic training in physiology, medicine, biology, and biochemistry at the Christian Medical College, Vellore, The University of Nebraska, and Washington University in St. Louis.  He also has formal training and certification in internal medicine, hematology, and oncology. Dr. Varki’s research interests include the role of sialic acids in viral and bacterial infections, regulation of the immune response, initiation and progression of tumors, and unique aspects of human evolution.

Sundar Subramaniam, MS, MBA – Board of Directors

Sundar Subramaniam is Chairman of IBCC, whose holdings include Cambridge Technology Enterprises, Knome, MTPV, Cambridge Energy Resources, ThriveHive and DNSstuff. He is Chairman of Knome and Sialix and General Partner at Higher Moment Capital.  He previously served as Chairman of I-Cube, C-bridge, Open Environment Corporation, and OneWave – all of which completed IPO’s and Answerfriend (Inquira, acq Oracle), WorldStreet (acq Thomson Reuters) and Integrated Computing Engines (acq Media100), director of DNSstuff (acq Solarwinds) and Managing Partner of Cambridge Samsung Partners, a Venture Capital firm.

Brad Curley, BS, CPA - Board of Directors

Brad Curley is a member of Boston Harbor Angels and an adjunct professor at Boston College. He was with KPMG LLP for more than 25 years providing services to clients in many industries. Brad was Partner in Charge of KPMG’s New England Area Internal Audit, Risk and Compliance Services practice and also served as the Firm’s Advisory Services practice leader for Northeast Area middle market accounts. He is a member of Board Leaders, the Corporate Directors Group and the National Association of Corporate Directors.